Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reference-Cited by-同舟云学术

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Published:2020-03-01 Issue:3 Volume:6 Page:375
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Duan Jianchun¹,Cui Longgang²,Zhao Xiaochen²,Bai Hua¹,Cai Shangli²,Wang Guoqiang²,Zhao Zhengyi²,Zhao Jing²,Chen Shiqing²,Song Jia²,Qi Chuang²,Wang Qing²,Huang Mengli²,Zhang Yuzi²,Huang Depei²,Bai Yuezong²,Sun Feng³,Lee J. Jack⁴,Wang Zhijie¹,Wang Jie¹

Affiliation:

1. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. The Medical Department, 3D Medicines Inc, Shanghai, China

3. School of Public Health, Department of Epidemiology and Biostatistics, Peking University Health Science Centre, Beijing, China

4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2757522/jamaoncology_duan_2019_oi_190099.pdf

Reference56 articles.

1. Cancer immunotherapy using checkpoint blockade.;Ribas;Science,2018

2. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.;Tang;Nat Rev Drug Discov,2018